Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion type Assertion NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_head.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion description "[These results suggest that assessment of GSC MGMT and CD133 levels will guide future clinical targeted therapies and stratify glioma patient treatment regimens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_provenance.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion evidence source_evidence_literature NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_provenance.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion SIO_000772 21769436 NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_provenance.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion wasDerivedFrom befree-20140225 NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_provenance.
- NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_assertion wasGeneratedBy ECO_0000203 NP366772.RAzZnM6Sj7wRB2qy9U0QhCtiZEPFctqbvBiRifqfdw7rg130_provenance.